Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 128 Melanoma 65 Squamous Cell Carcinoma of Head and Neck 64 Parkinson Disease 4, Autosomal Dominant Lewy Body 53 Lung Neoplasms 51 Triple Negative Breast Neoplasms 47 Neoplasm Metastasis 46 Breast Neoplasms 42 Neoplasms 39 Colorectal Neoplasms 34 Carcinoma, Renal Cell 30 Head and Neck Neoplasms 29 Endometrial Neoplasms 29 Ovarian Neoplasms 27 Carcinoma, Transitional Cell 23 Urinary Bladder Neoplasms 21 Stomach Neoplasms 18 Carcinoma 16 Pancreatic Neoplasms 15 Uterine Cervical Neoplasms 14 Esophageal Neoplasms 13 Brain Neoplasms 13 Recurrence 12 Sarcoma 11 Hodgkin Disease 11 Carcinoma, Squamous Cell 11 Carcinoma, Hepatocellular 11 Cholangiocarcinoma 10 Skin Neoplasms 9 Esophageal Squamous Cell Carcinoma 9

Interventions

pembrolizumab 1 liposomal doxorubicin 1 atezolizumab 1 Tumor Necrosis Factor-alpha 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Adenoviridae Infections × pembrolizumab × 90 days × Clear all

NCT05271318 2026-05-05

PROTA

TILT Biotherapeutics Ltd.

Phase 1/2 Active not recruiting

Adenoviridae Infections

Data powered by HemOnc (CC BY 4.0) Colophon ⚡